Samsung Biologics: A Beacon of Sustainability in the CDMO Industry

In the ever-evolving landscape of the contract development and manufacturing organization (CDMO) industry, one name stands out as a shining example of sustainability and commitment to environmental, social, and governance (ESG) principles: Samsung Biologics. The company's recent recognition in the Dow Jones Sustainability World Index (DJSI) for the fourth consecutive year is a testament to its unwavering dedication to responsible business practices and a healthier world.

Samsung Biologics' inclusion in the DJSI World Index is a reflection of its strong ESG performance across various aspects. In the environmental domain, the company has set ambitious targets to achieve net-zero greenhouse gas emissions and 100% renewable energy usage across its sites and supply chains by 2050. This commitment to reducing its carbon footprint and enhancing energy efficiency has positioned Samsung Biologics as a leader in the CDMO industry.



The company's social responsibility initiatives have also played a significant role in its ESG performance. Samsung Biologics has consistently invested in local communities through scholarships and medical outreach programs, fostering goodwill and positive brand perception. These efforts have not only enhanced the company's social score but also contributed to its overall ESG rating.

Samsung Biologics' commitment to transparency and ethical business practices has further bolstered its ESG credentials. The company has joined global initiatives like the Sustainable Markets Initiative (SMI) and the United Nations Global Compact, demonstrating its dedication to responsible value chain management and contributing to a healthier world.

As the CDMO industry continues to grow and evolve, Samsung Biologics' leadership in sustainability sets a high bar for its competitors. The company's comprehensive approach to ESG, including its ambitious environmental targets and community engagement, has positioned it as a trailblazer in the sector. By aligning its business practices with sustainable development goals, Samsung Biologics has not only improved its ESG performance but also solidified its reputation as a responsible corporate citizen.

In conclusion, Samsung Biologics' recognition in the DJSI World Index for the fourth consecutive year is a testament to its unwavering commitment to sustainability and responsible business practices. The company's leadership in the CDMO industry, driven by its ambitious environmental targets and community engagement, sets a high standard for its competitors and contributes to a healthier, more sustainable world. As the global biopharmaceutical industry continues to grow, Samsung Biologics' commitment to sustainability will undoubtedly play a crucial role in shaping its future.